Tabula Rasa HealthCare Takes First Step Toward IPO
The U.S. Securities and Exchange Commission (SEC) has received a filing from Tabula Rasa HealthCare regarding its initial public offering (IPO).
The U.S. Securities and Exchange Commission (SEC) has received a filing from Tabula Rasa HealthCare regarding its initial public offering (IPO).
Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The company announced the presentation of positive data from subgroup analyses of METEOR, the Phase…
Janney Capital has weighed in on biotech company Acceleron Pharma and what its outlook stands to be for the future.
MannKind Corp. (NASDAQ: MNKD) is one of the most traded biotech companies on the market, and one of the most shorted as well. In Tuesday’s session the stock took a big downturn after the…
Akebia Therapeutics plans on raising capital, according to its most recent proposed public offering.
Bavarian Nordic has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as a year with some uncertainty.
24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added some color.
Sancilio Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Fitch commented on the omnibus spending bill signed into law on December 18 that provides U.S. health insurers with a short-term reprieve by delaying the levy of three key Affordable Care Act (ACA) corporate…
KaloBios Pharmaceuticals filed for Chapter 11 bankruptcy on Tuesday morning, over a week after former CEO Martin Shkreli was arrested by the FBI for securities fraud.
NeuroMetrix might be turning itself around with the launch of its system for detecting diabetic neuropathy.
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
Valeant Pharmaceuticals watched its shares move lower in Monday’s trading session on a health scare from one of its top executives.
Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.